[go: up one dir, main page]

MA34221B1 - Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs - Google Patents

Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Info

Publication number
MA34221B1
MA34221B1 MA35354A MA35354A MA34221B1 MA 34221 B1 MA34221 B1 MA 34221B1 MA 35354 A MA35354 A MA 35354A MA 35354 A MA35354 A MA 35354A MA 34221 B1 MA34221 B1 MA 34221B1
Authority
MA
Morocco
Prior art keywords
robo1
fusion protein
tumor treatment
protein
relates
Prior art date
Application number
MA35354A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Tarik Dabdoubi
Frederique Dol-Gleizes
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34221(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34221B1 publication Critical patent/MA34221B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une protéine recombinante Robo1-Fc et son utilisation pour traiter les maladies dans lesquelles une protéine Slit est surexprimée, en particulier le cancer. Elle concerne également une composition comprenant une telle protéine recombinante. Un autre aspect de l'invention consiste en l'utilisation d'une molécule Robo1-Fc en tant qu'outil de diagnostic pour détecter la surexpression d'une molécule de la famille Slit chez un patient.
MA35354A 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs MA34221B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
PCT/FR2011/050811 WO2011128561A1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
MA34221B1 true MA34221B1 (fr) 2013-05-02

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35354A MA34221B1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Country Status (27)

Country Link
US (1) US9493529B2 (fr)
EP (1) EP2558489A1 (fr)
JP (1) JP5858442B2 (fr)
KR (1) KR20130059329A (fr)
CN (1) CN102884076A (fr)
AR (1) AR080891A1 (fr)
AU (1) AU2011239839B2 (fr)
BR (1) BR112012026020A2 (fr)
CA (1) CA2796303A1 (fr)
CL (1) CL2012002879A1 (fr)
CR (1) CR20120508A (fr)
DO (1) DOP2012000265A (fr)
EA (1) EA201291044A1 (fr)
EC (1) ECSP12012230A (fr)
FR (1) FR2958936A1 (fr)
GT (1) GT201200275A (fr)
IL (1) IL222382A (fr)
MA (1) MA34221B1 (fr)
MX (1) MX338981B (fr)
NI (1) NI201200155A (fr)
PE (1) PE20130199A1 (fr)
PH (1) PH12012502044A1 (fr)
SG (1) SG184529A1 (fr)
TN (1) TN2012000473A1 (fr)
TW (1) TW201142024A (fr)
UY (1) UY33334A (fr)
WO (1) WO2011128561A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69415627T2 (de) 1993-04-05 1999-06-17 Daikin Industries, Ltd., Osaka Polytetrafluorethylenfaser, baumwollartiges, diese faser enthaltendes material, und verfahren zu deren herstellung
US20130273049A1 (en) * 2010-12-23 2013-10-17 Sanofi Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
EP3455243B1 (fr) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Matrice de séparation
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
BR112019024742A2 (pt) * 2017-06-02 2020-06-16 Pfizer Inc. Proteínas robo2 recombinantes, composições, métodos e usos das mesmas
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
KR102353524B1 (ko) * 2019-02-27 2022-01-20 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 골 관련 질환 예방 또는 치료용 조성물
CA3136663A1 (fr) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions et methodes utiles pour favoriser la production de lait
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP2003517262A (ja) * 1997-10-20 2003-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経誘導に含まれるポリペプチド及び核酸のファミリーであるｒｏｂｏ
NZ507063A (en) 1998-04-02 2003-11-28 Rigel Pharmaceuticals Inc Self-dimerising peptides causing the formation of compact structures
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
US20080153104A1 (en) * 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
WO2005073383A2 (fr) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Proteines de fusion heterodimere de l'hormone-fc stimulant les follicules (fsh-fc) utiles dans le traitement de l'infertilite
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
US20130195881A1 (en) * 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
MX2010001975A (es) 2007-08-29 2010-03-10 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent

Also Published As

Publication number Publication date
IL222382A (en) 2016-06-30
CN102884076A (zh) 2013-01-16
CA2796303A1 (fr) 2011-10-20
CR20120508A (es) 2012-11-01
UY33334A (es) 2011-12-01
FR2958936A1 (fr) 2011-10-21
PE20130199A1 (es) 2013-03-09
IL222382A0 (en) 2012-12-31
MX338981B (es) 2016-05-06
US9493529B2 (en) 2016-11-15
US20130039912A1 (en) 2013-02-14
EP2558489A1 (fr) 2013-02-20
TN2012000473A1 (fr) 2014-01-30
PH12012502044A1 (en) 2017-07-26
SG184529A1 (en) 2012-11-29
AU2011239839A1 (en) 2012-11-08
KR20130059329A (ko) 2013-06-05
WO2011128561A1 (fr) 2011-10-20
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
EA201291044A1 (ru) 2013-04-30
TW201142024A (en) 2011-12-01
ECSP12012230A (es) 2012-11-30
CL2012002879A1 (es) 2013-03-22
AU2011239839B2 (en) 2015-08-20
MX2012011822A (es) 2012-11-12
DOP2012000265A (es) 2013-02-28
NI201200155A (es) 2013-02-05
BR112012026020A2 (pt) 2016-06-28
AR080891A1 (es) 2012-05-16
GT201200275A (es) 2014-01-24

Similar Documents

Publication Publication Date Title
MA34221B1 (fr) Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2007091250A3 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2008101985A3 (fr) Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
PE20110217A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
JO3265B1 (ar) مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
WO2004108139A3 (fr) Utilisation de composes heterocycliques en tant qu'inhibiteurs de scce
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
EP2285989A4 (fr) Nouvelles cibles permettant de réguler l'angiogenèse
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
DE602007007618D1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2009105457A3 (fr) Marqueurs du cancer slit2
Zhu et al. Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MA37961A1 (fr) Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation
WO2008090332A3 (fr) Polymorphismes du facteur h dans le diagnostic et la thérapie de maladies inflammatoires telles que la dégénérescence maculaire liée à l'âge
EP4218786A3 (fr) Opiorphine destinée à être utilisée comme agent analgésique
MA34480B1 (fr) Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
ATE506961T1 (de) Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
TW200610530A (en) Anti-parasitic uses of borinic acid complexes